Printer Friendly

ARAMED AND GENSIA INTEND TO VIGOROUSLY DEFEND LAWSUIT

 ARAMED AND GENSIA INTEND TO VIGOROUSLY DEFEND LAWSUIT
 SAN DIEGO, Oct. 22 /PRNewswire/ -- Gensia Pharmaceuticals Inc.


(NASDAQ: GNSA) and Aramed Inc. (NASDAQ: ARAMZ) today announced that they intend to vigorously defend a lawsuit filed Oct. 9, 1992, in the U.S. District Court for the Southern District of California, accusing Aramed, certain of its officers and directors, Gensia and its directors of violating securities laws.
 The lawsuit alleges a violation of federal and state law arising out of an alleged failure to disclose information about the efficacy and testing of Gensia's Arasine drug during the period from Feb. 27 to Sept. 22, 1992. The allegations are similar to those in lawsuits previously filed in the same court against Gensia and its directors. The suit seeks damages on behalf of an alleged class of investors who purchased Aramed units during that period. The complaint does not specify any amount of claimed damages.
 Aramed and Gensia stated that they believe the lawsuit lacks merit and appears to have been filed as an automatic response to a decrease on Sept. 22 in the market price of Aramed units. "We are confident that Aramed and Gensia have complied with applicable laws, and that Gensia's efforts to develop Arasine were adequately disclosed," said David F. Hale, chairman, president and chief executive officer of Gensia.
 Gensia Pharmaceuticals in a San Diego-based biopharmaceutical company formed to discover, develop, manufacture and market novel pharmaceutical products for the treatment and diagnosis of human disease. Aramed was formed to accelerate the discovery, research and development of certain compounds utilizing Gensia's adenosine regulating agent technology.
 -0- 10/22/92
 /CONTACT: Martha L. Hough or Elizabeth A. Gard of Gensia Pharmaceuticals, 619-546-8300/
 (GNSA ARAMZ) CO: Gensia Pharmaceuticals Inc.; Aramed Inc. ST: California IN: MTC SU:


JL-JB -- SD005 -- 3330 10/22/92 09:02 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 22, 1992
Words:302
Previous Article:IBM COLOR JETPRINTER PS FROM LEXMARK LOWERS PRICE POINT FOR POSTSCRIPT-COMPATIBLE DESKTOP COLOR PRINTING; USES NEW RISC TECHNOLOGY
Next Article:FIRSTFED ANNOUNCES THIRD QUARTER EARNINGS
Topics:


Related Articles
ALLIANCE PHARMACEUTICAL CORP. ANNOUNCES SHAREHOLDER LAWSUITS
GENSIA INTENDS TO VIGOROUSLY DEFEND LAWSUIT
ARAMED REPORTS 1994 FIRST QUARTER RESULTS
GENSIA RESPONDS TO SHAREHOLDER LAWSUIT
ARAMED RESPONDS TO SHAREHOLDER LAWSUIT
GENSIA AND ARAMED INITIATE PHASE 1 TRIAL WITH ARA COMPOUND
GENSIA AND ARAMED ANNOUNCE SETTLEMENT OF SHAREHOLDERS' LITIGATION
Knoll Pharmaceutical Company Statement Concerning Synthroid(R) Lawsuit Filed in U.S. District Court, San Francisco
Gensia Sicor Announces Settlement with Great Lakes Chemical Corporation.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters